Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Gross Profit (2016 - 2025)

Amphastar Pharmaceuticals (AMPH) has 13 years of Gross Profit data on record, last reported at $85.7 million in Q4 2025.

  • For Q4 2025, Gross Profit fell 1.13% year-over-year to $85.7 million; the TTM value through Dec 2025 reached $356.1 million, down 4.76%, while the annual FY2025 figure was $356.1 million, 4.76% down from the prior year.
  • Gross Profit reached $85.7 million in Q4 2025 per AMPH's latest filing, down from $98.6 million in the prior quarter.
  • Across five years, Gross Profit topped out at $108.4 million in Q3 2023 and bottomed at $44.9 million in Q1 2021.
  • Average Gross Profit over 5 years is $76.5 million, with a median of $79.5 million recorded in 2023.
  • Peak YoY movement for Gross Profit: soared 85.27% in 2023, then decreased 9.87% in 2024.
  • A 5-year view of Gross Profit shows it stood at $56.2 million in 2021, then grew by 26.56% to $71.2 million in 2022, then soared by 35.09% to $96.1 million in 2023, then decreased by 9.87% to $86.6 million in 2024, then fell by 1.13% to $85.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Gross Profit were $85.7 million in Q4 2025, $98.6 million in Q3 2025, and $86.5 million in Q2 2025.